MultiModal Imaging Services Corporation (dba HealthLytix, now part of CorTechs Labs)

San Diego, California, USA  All United States companies → Founded 1996
Imaging AI Specialist Specialty-Focused AI
Oncology Radiology Urology
Oncology AI
Series C — $23.1M

Products

RSI-MRI+
MultiModal Imaging Services Corporation (dba HealthLytix, now part of CorTechs Labs)
Oncology AI
RSI-MRI+ is an FDA-cleared AI-powered imaging software by HealthLytix (now CorTechs Labs) that uses Restriction Spectrum Imaging (RSI) to enhance the detection and diagnosis of prostate cancer through improved visualization and quantification of restricted water in MRI scans.

See all 1 product →

About MultiModal Imaging Services Corporation (dba HealthLytix, now part of CorTechs Labs)

CorTechs Labs, now operating as Cortechs.ai, is a leading healthcare AI company specializing in advanced medical imaging software for the detection, diagnosis, and monitoring of neurological and oncological diseases. The company merged with its sister company, HealthLytix, in June 2020, which expanded its capabilities to include AI-powered tools for cancer screening and early detection, particularly prostate and brain cancer.

For physicians, Cortechs.ai offers a comprehensive suite of FDA-cleared and CE-marked quantitative imaging solutions. These include NeuroQuant®, which provides automated volumetric MRI analysis for neurodegenerative conditions like Alzheimer’s disease, epilepsy, multiple sclerosis, and brain trauma. The integration of HealthLytix brought RSI-MRI+ for Prostate, an advanced imaging software that improves early detection and diagnosis of prostate cancer using restriction spectrum imaging, and CT CoPilot for head CT exams. These AI-powered tools aim to enhance diagnostic accuracy, reduce subjectivity, and streamline clinical workflows, ultimately supporting better patient care and treatment planning.

Focus Areas

AI Medical Imaging Genetics Prostate Cancer Detection Neurodegenerative Diseases Brain Imaging Early Detection Risk Prediction Quantitative Image Analysis Oncology Radiology Workflow

Business Intelligence

Key InvestorsDragasac Limited, VILAS Ventures, Genting Berhad
PartnershipsNuance AI Marketplace, Blackford, Subtle Medical, Imaging Biometrics, Strategic Radiology, ALZ-NET
AcquisitionsAcquired by CorTechs Labs (now Cortechs.ai)
TechnologyCloud-native, AI-driven image analysis, machine learning, Restriction Spectrum Imaging (RSI), volumetric MRI processing
FDA Clearances2 cleared products (estimated)

What Physicians Need to Know

AI & Medical Imaging
Specializes in cutting-edge AI, machine learning, and deep learning algorithms for advanced medical image analysis across various modalities (MRI, CT, PET, X-ray). Their solutions aim to revolutionize disease screening and early detection.
Prostate Cancer Detection
Offers RSI-MRI+, an FDA-cleared imaging software utilizing Restriction Spectrum Imaging (RSI) for improved early detection and diagnosis of prostate cancer. It provides automatic prostate segmentation, quantification, and reporting.
Neurodegenerative Diseases
Provides a comprehensive suite of quantitative neuroimaging software, including NeuroQuant, LesionQuant, and PETQuant, to aid in the assessment and monitoring of conditions like Alzheimer's disease, epilepsy, multiple sclerosis, and brain trauma.
Brain Imaging & Analysis
Key products like NeuroQuant offer FDA-cleared volumetric MR processing, LesionQuant enables automated lesion segmentation and quantification (especially FLAIR lesions), and PETQuant provides rapid automated analysis of PET brain studies. CT CoPilot is an FDA-cleared quantitative imaging solution for head CT exams.
Early Detection & Risk Prediction
A core mission is to improve screening and early detection for various cancers (prostate, brain - pending approval) and neurodegenerative diseases, leveraging advanced imaging and integrated genetic risk analysis.
Quantitative Image Analysis
All solutions focus on providing objective, reproducible, and quantitative measurements of anatomical structures and lesions, replacing time-consuming manual processes with automated technology.
Oncology
Beyond prostate cancer, the company is expanding into other oncology areas, with pending approval for early detection of brain cancer and capabilities in interpretable AI for chest X-ray.
Radiology Workflow
Solutions like CT CoPilot are designed to improve workflow efficiency, measurement accuracy, and clinical confidence by providing consistent views and automated quantitative measurements for head CT exams.
Genetics Integration
Offers integrated genetic risk analysis capabilities, combining genetic insights with medical imaging for a more comprehensive understanding of disease pathology.
Physician Tip

For physicians, HealthLytix (now CorTechs Labs) stands out by offering FDA-cleared, AI-powered tools that deliver faster, more accurate, and objective diagnostic support. These solutions reduce subjectivity in image interpretation, improve workflow efficiency through automation, and provide quantitative data crucial for monitoring disease progression and treatment effectiveness. The ability to detect diseases like prostate cancer and neurodegenerative conditions earlier, combined with integrated genetic insights, empowers physicians to make more informed and timely clinical decisions, ultimately optimizing patient care. The products are designed for easy integration with existing PACS systems, streamlining adoption into current radiology workflows.

The company's software solutions are designed to be platform-independent, operating on Mac, Windows, or Linux (Ubuntu) based systems for local installations. They accept DICOM image data as input and are built for easy integration with existing PACS (Picture Archiving and Communication Systems) solutions, enabling seamless incorporation into clinical environments.

Products by MultiModal Imaging Services Corporation (dba HealthLytix, now part of CorTechs Labs)

1 product in the directory

RSI-MRI+
MultiModal Imaging Services Corporation (dba HealthLytix, now part of CorTechs Labs)
Oncology AI
RSI-MRI+ is an FDA-cleared AI-powered imaging software by HealthLytix (now CorTechs Labs) that uses Restriction Spectrum Imaging (RSI) to enhance the detection and diagnosis of prostate cancer through improved visualization and quantification of restricted water in MRI scans.

Reviews & Opinions

No web reviews on file yet for MultiModal Imaging Services Corporation (dba HealthLytix, now part of CorTechs Labs). Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about MultiModal Imaging Services Corporation (dba HealthLytix, now part of CorTechs Labs).

Loading videos...

Videos load interactively. If none appear, search YouTube for MultiModal Imaging Services Corporation (dba HealthLytix, now part of CorTechs Labs) →

View all on YouTube

Press & Coverage

Cortechs.ai
Cortechs.ai and HealthLytix announce merger
Cortechs.ai Inc. merged with HealthLytix in June 2020, combining their medical image analysis software to offer a comprehensive suite for various neurological conditions and cancer detection. The merged company operates under the Cortechs.ai brand and aims to broaden its offerings to its global network of clinical sites.
2020-06
PR Newswire (via HealthLytix)
HealthLytix Receives FDA Clearance for Breakthrough Prostate Imaging Solution, RSI-MRI+
HealthLytix announced in November 2019 that it received FDA 510(k) clearance for its RSI-MRI+ software, a breakthrough prostate imaging solution utilizing an advanced diffusion MRI technique and AI to improve early detection and diagnosis of prostate cancer. This software increases the visibility of restricted water, a hallmark of cancerous tissue.
2019-11
Medical Buyer
HealthLytix Joins Nuance AI Marketplace For Diagnostic Imaging
In January 2020, HealthLytix announced that its CT CoPilotu00ae application for head CT exams would be available on the Nuance AI Marketplace, providing radiologists with AI diagnostic models within their reporting platform. CT CoPilot automates quantification of intracranial structures and identifies changes over time to improve reading efficiency and accuracy.
2020-01
Cortechs.ai
CorTechs Labs Announces Company Rebrand to Cortechs.ai at RSNA 2020
CorTechs Labs Inc. rebranded to Cortechs.ai in November 2020, reflecting the company's evolution in AI imaging software and its expanded focus beyond neuroimaging to include oncology. This rebrand followed the merger with HealthLytix earlier in the year, which broadened their AI-powered tools.
2020-11
Cortechs.ai
Cortechs.ai awarded million dollar NIH grant
Cortechs.ai received a $1.35 million, 2.5-year grant from the National Institutes of Health (NIH) in August 2022 to advance Alzheimer's Disease diagnosis. The grant supports the development of an automated AI solution to quantify microstructural changes using Restriction Spectrum Imaging.
2022-08
Applied Radiology
Cortechs.AI Receives NIH Grant to Develop ARIA Detection Software
Cortechs.ai announced in August 2024 a three-year, multimillion-dollar NIH grant to develop software for automatically detecting and quantifying Amyloid Related Imaging Abnormalities (ARIA) in Alzheimer's patients undergoing treatment. This aims to monitor therapeutic effects and improve patient management.
2024-08
Applied Radiology
Cortechs.ai Nets FDA Clearance for NeuroQuant 5.0 with Improved ARIA Quantification
In September 2024, Cortechs.ai received FDA 510(k) clearance for its NeuroQuant 5.0 software, which offers advanced segmentation and quantification for MRI lesions related to ARIA in Alzheimer's patients. This update enhances visualization and calculations through deep-learning based technology.
2024-09
PR Newswire (via Cortechs.ai)
Cortechs.ai Collaborates with Microsoft to Bring AI-Powered Imaging Insights Directly into Radiology Workflows
Cortechs.ai announced a strategic collaboration with Microsoft in June 2026 to integrate AI-driven imaging biomarkers and insights into clinical radiology workflows. This partnership aims to enhance diagnostic precision and streamline reporting by leveraging Microsoft Azure's cloud infrastructure.
2026-06

Frequently Asked Questions

CorTechs.ai offers RSI-MRI+, an FDA-cleared imaging software that utilizes artificial intelligence and Restriction Spectrum Imaging (RSI) to enhance the visibility of restricted water, a hallmark of cancerous tissue. This technology aids clinicians in the early detection and diagnosis of prostate cancer by providing improved visualization and quantification compared to conventional diffusion MRI.
CorTechs.ai's flagship product, NeuroQuantu00ae, is an FDA-cleared AI-powered software that provides automated volumetric measurements of brain structures from MRI scans. It helps clinicians identify and assess neurodegeneration in its earliest stages for conditions like Alzheimer's disease, multiple sclerosis, epilepsy, and traumatic brain injury, by comparing patient brain volumes to a normative database.
CorTechs.ai's solutions, including NeuroQuant and OnQu2122 Prostate, are designed for seamless integration into existing PACS systems and radiology workflows. They automate time-consuming manual processes, providing fast, objective quantitative reports and color-coded brain structure analyses that enhance diagnostic accuracy and efficiency.
CorTechs.ai's key products, such as RSI-MRI+ and NeuroQuant, have received FDA 510(k) clearance as medical devices, demonstrating their safety and effectiveness. Furthermore, their cloud-based processing systems are HIPAA compliant and HITRUST CSF certified in the US, ensuring maximal protection of patient health information through secure, encrypted data transfer and storage.
While specific details on pricing are not publicly available, CorTechs.ai emphasizes providing cost-effective solutions and offers support resources including a dedicated support page, ticket submission, training videos, and CPT codes for reimbursement. They are committed to providing up-to-date infrastructure, privacy, security, and compliance for their cloud processing systems.
CorTechs.ai actively engages in strategic partnerships, such as with deepc for seamless AI integration into clinical workflows and Siemens Healthineers for global distribution and integration into MR systems. These collaborations expand the accessibility of their clinically validated AI solutions, streamline deployment, and enhance diagnostic precision for a broader global market.
While HealthLytix initially focused on advances in both genetics and medical imaging, the merged entity, CorTechs.ai, primarily emphasizes cutting-edge AI applications in medical imaging for disease screening and early detection. Their current product portfolio is heavily centered on quantitative image analysis for conditions like prostate cancer and neurodegenerative diseases.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.